A股異動 | 景峯醫藥跌停 口罩產品預計產生的收入佔全年營收比重很小
格隆匯4月14日丨此前6個交易日錄得5個漲停板的景峯醫藥(000908.SZ)今日跌停,現報5.58元,暫成交4.7億元,最新總市值49億元。公司昨日晚間發公告稱,公司一次性非無菌口罩和醫用外科口罩按照目前訂單情況,預計收入約十餘萬元,但是相較於公司年銷售額數十億元的藥品收入,口罩產品預計產生的收入佔公司全年營業收入的比重很小,且實際銷售情況受疫情防控進展、市場供求狀況等多方面因素影響,預計對公司業績影響較小。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.